Jones Trading upgraded shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) to a strong-buy rating in a report issued on Monday,Zacks.com reports.
A number of other equities research analysts have also recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an "overweight" rating on the stock. Scotiabank assumed coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective for the company. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 price target on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $43.50.
View Our Latest Stock Report on Palvella Therapeutics
Palvella Therapeutics Trading Up 1.2 %
NASDAQ:PVLA traded up $0.34 during trading hours on Monday, reaching $28.10. The stock had a trading volume of 74,902 shares, compared to its average volume of 62,262. The firm has a market capitalization of $315.31 million, a PE ratio of -2.32 and a beta of 0.54. The stock has a 50 day moving average of $20.24. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27.
Hedge Funds Weigh In On Palvella Therapeutics
A number of hedge funds have recently modified their holdings of the company. Citadel Advisors LLC bought a new stake in shares of Palvella Therapeutics in the fourth quarter worth about $125,000. Toronto Dominion Bank purchased a new stake in Palvella Therapeutics in the 4th quarter worth approximately $159,000. Geode Capital Management LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $171,000. Cresset Asset Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter valued at approximately $251,000. Finally, Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics during the fourth quarter valued at approximately $256,000. Hedge funds and other institutional investors own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
